News from ohr pharmaceutical inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 09, 2013, 09:10 ET

Ohr Pharmaceutical to Present at the Wedbush Life Sciences Management Access Conference on August 14th

 Ohr Pharmaceutical (NasdaqCM: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Aug 07, 2013, 09:00 ET

Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board

Ohr Pharmaceutical Inc. (NasdaqCM: OHRP) today announced the addition of John J. Wroblewski M.D. to its Scientific Advisory Board ("SAB"). The...

Jul 10, 2013, 06:55 ET

Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial

Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Jun 12, 2013, 06:55 ET

Ohr Pharmaceutical Announces Approval for Listing on NASDAQ

 Ohr Pharmaceutical, Inc. (OTCQB: OHRPD), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical...

Jun 03, 2013, 06:55 ET

Ohr Pharmaceutical Announces Reverse Split of Common Stock

 Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical...

May 29, 2013, 12:33 ET

Ohr Pharmaceutical to Present at the Marcum MicroCap Conference on May 30th

Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...

May 22, 2013, 08:30 ET

Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs,...

May 02, 2013, 07:00 ET

Ohr Pharmaceutical Appoints Thomas M. Riedhammer To Board Of Directors

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs,...

Apr 22, 2013, 07:00 ET

Ohr Pharmaceutical Announces $5 Million Financing from Exercise of Warrants

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs,...

Mar 21, 2013, 06:30 ET

Ohr Pharmaceutical Announces Results from OHR/AVR118 Phase II Trial in Cancer Cachexia

 Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Feb 07, 2013, 09:15 ET

Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference

 Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical...

Jan 03, 2013, 09:15 ET

Ohr Pharmaceutical To Present At Biotech Showcase 2013 in San Francisco

  Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Dec 27, 2012, 09:15 ET

Ohr Pharmaceutical Provides Update to Shareholders on 2012 Accomplishments and Milestones for 2013

 Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in...

Nov 20, 2012, 08:15 ET

Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board

 Ohr Pharmaceutical Inc. (OTCBB: OHRP) today announced the addition of two prominent ophthalmologists to its Scientific Advisory Board ("SAB")...

Oct 05, 2012, 09:20 ET

Ohr Pharmaceutical to Present at the 11th Annual BIO Investor Forum

 Ohr Pharmaceutical (OTCBB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs,...

Sep 24, 2012, 08:10 ET

Ohr Pharmaceutical Initiates Phase II Trial of Squalamine Eye Drops For The Treatment Of Wet Macular Degeneration

 Ohr Pharmaceutical (OTCBB: OHRP-News) today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of...